摘要
目的探索维莫非尼在BRAF基因突变的肢端和黏膜型黑色素瘤患者治疗中的有效性和安全性。方法回顾性分析2011年1月—2016年1月在北京大学肿瘤医院确诊为BRAF基因突变的肢端或黏膜型黑色素瘤住院、并接受维莫非尼治疗患者(24例)的临床资料,随访数据截至2017年1月,所有患者均出现死亡终点。利用Fisher确切概率法检验肢端型和黏膜型黑色素瘤患者的基线资料差异,Kaplan-Meier法分析患者的生存期和无进展生存期,Log rank法检验两种类型黑色素瘤患者生存数据的差异。结果基线资料在肢端和黏膜型黑色素瘤患者之间差异无统计学意义。总体的中位生存期和中位无进展生存期分别为8.0月和4.9月。肢端和黏膜型黑色素瘤患者的中位生存期、中位无进展生存期、疾病控制率差异均无统计学意义。维莫非尼不良事件多为3级以下,患者耐受性良好。结论与皮肤型黑色素瘤相似,维莫非尼在BRAF基因突变的肢端和黏膜型黑色素瘤患者中的有效性和安全性良好。
Objective To explore the efficacy and safety of Vemurafenib in acral and mucosal melanoma patients with BRAF gene mutation.Methods We retrospectively analyzed the clinical data of 24 patients diagnosed as BRAF gene-mutant acral melanoma(AM)or mucosal melanoma(MM)hospitalized in Peking University Cancer Hospital from January 2011 to January 2016.All patients had died by the follow-up cutoff date of January 2017.Fisher exact test was used to detect the difference of baseline characteristics between AM and PM patients.Kaplan-Meier method was used for the estimation of overall survival(OS)and progressionfree survival(PFS).We compared patients’survival data between two melanoma types using Log rank test.Results There was no statistical difference in baseline characteristics between AM and MM patients.Overall median OS and PFS were 8.0 and 4.9 months.No statistical difference was found in median OS,median PFS or disease control rate.The severity of most adverse events was less than grade 3.Vemurafenib was well tolerated during patients’treatment.Conclusion Vemurafenib has acceptable efficacy and safety in BRAFgene-mutant AM and MM patients,which is similar to that in cutaneous melanoma patients.
作者
魏晓婷
白雪
毛丽丽
迟志宏
盛锡楠
崔传亮
王轩
连斌
唐碧霞
鄢谢桥
李思明
周莉
郭军
斯璐
WEI Xiaoting;BAI Xue;MAO Lili;CHI Zhihong;SHENG Xi’nan;CUI Chuanliang;ANG Xuan;LIAN Bin;TANG Bixia;YAN Xieqiao;LI Siming;ZHOU Li;GUO Jun;SI Lu(Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Department of Renal Cancer and Melanoma,Peking University Cancer Hospital&Institute,Beijing 100142,China)
出处
《肿瘤防治研究》
CAS
CSCD
2018年第11期879-882,共4页
Cancer Research on Prevention and Treatment
